# N Acetyl Cysteine Cognition Randomized Trial: What the Evidence Says
Canonical: https://www.migaku.app/guides/n-acetyl-cysteine-cognition-randomized-trial-evidence-review
Category: evidence-review
Summary: N Acetyl Cysteine Cognition Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pas
Last reviewed: 2026-07-28
Reviewed by: Migaku Evidence Review
# N Acetyl Cysteine Cognition Randomized Trial: What the Evidence Says

## Quick Answer

N Acetyl Cysteine Cognition Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 randomized trial, 1 research article.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| N-acetyl cysteine for the treatment of alcohol use disorder: study protocol for a multi-site, double-blind randomised controlled trial (NAC-AUD study) | randomized trial | 2 | 2025-01-01 | 10.1136/bmjopen-2024-091631 |
| 669. N-ACETYL-CYSTEINE (NAC) INTERVENTION AND MITOCHONDRIAL MECHANISMS IN- EARLY PSYCHOSIS PATIENTS | research article | 4 | 2025-08-01 | 10.1093/ijnp/pyaf052.351 |

## What The Sources Report

- Clinical studies involving a range of neuropsychiatric disorders have demonstrated that NAC is well tolerated and has a good safety profile.Signs of efficacy have been observed for disorders similarly associated with impulse control including gambling disorderand skin picking,although these studies were relatively small. [Morley Kirsten (2025); evidence level 2]
- A secondary analysis of alcohol consumption in individuals with cannabis use disorder randomised to NAC (2400 mg/day) vs placebo found significant increases in alcohol abstinence and reduction in weekly drinking days for NAC vs placebo. [Morley Kirsten (2025); evidence level 2]
- Schizophrenia (SZ) is associated with neurocognitive dysfunction already in the early phase of the disease. [Khadimallah I (2025); evidence level 4]
- Individuals with SZ show increased oxidative damage and reduced antioxidant capacity. [Khadimallah I (2025); evidence level 4]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For n acetyl cysteine cognition randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Morley Kirsten (2025). N-acetyl cysteine for the treatment of alcohol use disorder: study protocol for a multi-site, double-blind randomised controlled trial (NAC-AUD study). DOI: 10.1136/bmjopen-2024-091631. PMCID: PMC12421191. PMID: 40921646. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12421191/
- Khadimallah I (2025). 669. N-ACETYL-CYSTEINE (NAC) INTERVENTION AND MITOCHONDRIAL MECHANISMS IN- EARLY PSYCHOSIS PATIENTS. DOI: 10.1093/ijnp/pyaf052.351. PMCID: PMC12359389. License: https://creativecommons.org/licenses/by-nc/4.0/ https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Acces.... https://pmc.ncbi.nlm.nih.gov/articles/PMC12359389/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.